Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68

1.

The first CNS-active carborane: A novel P2X7 receptor antagonist with antidepressant activity.

Wilkinson SM, Gunosewoyo H, Barron ML, Boucher A, McDonnell M, Turner P, Morrison DE, Bennett MR, McGregor IS, Rendina LM, Kassiou M.

ACS Chem Neurosci. 2014 May 21;5(5):335-9. doi: 10.1021/cn500054n. Epub 2014 Apr 3. Review.

2.

Pharmacology of a novel central nervous system-penetrant P2X7 antagonist JNJ-42253432.

Lord B, Aluisio L, Shoblock JR, Neff RA, Varlinskaya EI, Ceusters M, Lovenberg TW, Carruthers N, Bonaventure P, Letavic MA, Deak T, Drinkenburg W, Bhattacharya A.

J Pharmacol Exp Ther. 2014 Dec;351(3):628-41. doi: 10.1124/jpet.114.218487. Epub 2014 Sep 30.

3.
4.

The evolution of P2X7 antagonists with a focus on CNS indications.

Rech JC, Bhattacharya A, Letavic MA, Savall BM.

Bioorg Med Chem Lett. 2016 Aug 15;26(16):3838-45. doi: 10.1016/j.bmcl.2016.06.048. Epub 2016 Jun 30. Review.

PMID:
27426304
5.

Synthesis and SAR development of novel P2X7 receptor antagonists for the treatment of pain: part 2.

Brumfield S, Matasi JJ, Tulshian D, Czarniecki M, Greenlee W, Garlisi C, Qiu H, Devito K, Chen SC, Sun Y, Bertorelli R, Ansell J, Geiss W, Le VD, Martin GS, Vellekoop SA, Haber J, Allard ML.

Bioorg Med Chem Lett. 2011 Dec 15;21(24):7287-90. doi: 10.1016/j.bmcl.2011.10.037. Epub 2011 Oct 21.

PMID:
22078214
6.

P2X7 receptor: an emerging target in central nervous system diseases.

Sperlágh B, Illes P.

Trends Pharmacol Sci. 2014 Oct;35(10):537-47. doi: 10.1016/j.tips.2014.08.002. Epub 2014 Sep 12. Review.

PMID:
25223574
7.

Targeting purinergic receptors in islet transplantation.

Aikin RA.

Diabetes. 2013 May;62(5):1394-5. doi: 10.2337/db13-0211. No abstract available.

8.

[Advance in the research on P2X7 and inflammatory respiratory diseases].

Cao SH, Yuan SP, Hou Q.

Yao Xue Xue Bao. 2013 Aug;48(8):1183-8. Review. Chinese.

PMID:
24187823
9.

Feasibility study of B16 melanoma therapy using oxidized ATP to target purinergic receptor P2X7.

Hattori F, Ohshima Y, Seki S, Tsukimoto M, Sato M, Takenouchi T, Suzuki A, Takai E, Kitani H, Harada H, Kojima S.

Eur J Pharmacol. 2012 Nov 15;695(1-3):20-6. doi: 10.1016/j.ejphar.2012.09.001. Epub 2012 Sep 11.

PMID:
22981895
10.

Physiological roles and potential therapeutic applications of the P2X7 receptor in inflammation and pain.

Alves LA, Bezerra RJ, Faria RX, Ferreira LG, da Silva Frutuoso V.

Molecules. 2013 Sep 5;18(9):10953-72. doi: 10.3390/molecules180910953. Review.

11.

The role of P2X7 receptors in tissue fibrosis: a brief review.

Gentile D, Natale M, Lazzerini PE, Capecchi PL, Laghi-Pasini F.

Purinergic Signal. 2015 Dec;11(4):435-40. doi: 10.1007/s11302-015-9466-3. Epub 2015 Aug 29. Review.

12.

P2X7 antagonists as potential therapeutic agents for the treatment of CNS disorders.

Chrovian CC, Rech JC, Bhattacharya A, Letavic MA.

Prog Med Chem. 2014;53:65-100. doi: 10.1016/B978-0-444-63380-4.00002-0. Review.

PMID:
24418608
13.

Novel methyl substituted 1-(5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanones are P2X7 antagonists.

Rudolph DA, Alcazar J, Ameriks MK, Anton AB, Ao H, Bonaventure P, Carruthers NI, Chrovian CC, De Angelis M, Lord B, Rech JC, Wang Q, Bhattacharya A, Andres JI, Letavic MA.

Bioorg Med Chem Lett. 2015 Aug 15;25(16):3157-63. doi: 10.1016/j.bmcl.2015.06.004. Epub 2015 Jun 9.

PMID:
26099534
14.

Motor neuron dysfunction in a mouse model of ALS: gender-dependent effect of P2X7 antagonism.

Cervetto C, Frattaroli D, Maura G, Marcoli M.

Toxicology. 2013 Sep 6;311(1-2):69-77. doi: 10.1016/j.tox.2013.04.004. Epub 2013 Apr 11.

PMID:
23583883
15.

[Effect of P2X7 receptor on inflammatory diseases and its mechanism].

Xu H, Liang SD.

Sheng Li Xue Bao. 2013 Apr 25;65(2):244-52. Review. Chinese.

16.

P2X7 receptor antagonists: a patent review (2010-2015).

Park JH, Kim YC.

Expert Opin Ther Pat. 2017 Mar;27(3):257-267. doi: 10.1080/13543776.2017.1246538. Epub 2016 Oct 31. Review.

PMID:
27724045
17.

Receptor localization, native tissue binding and ex vivo occupancy for centrally penetrant P2X7 antagonists in the rat.

Able SL, Fish RL, Bye H, Booth L, Logan YR, Nathaniel C, Hayter P, Katugampola SD.

Br J Pharmacol. 2011 Jan;162(2):405-14. doi: 10.1111/j.1476-5381.2010.01025.x.

18.

P2 receptors for extracellular nucleotides in the central nervous system: role of P2X7 and P2Y₂ receptor interactions in neuroinflammation.

Weisman GA, Camden JM, Peterson TS, Ajit D, Woods LT, Erb L.

Mol Neurobiol. 2012 Aug;46(1):96-113. doi: 10.1007/s12035-012-8263-z. Epub 2012 Apr 1. Review.

19.

Preclinical characterization of substituted 6,7-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-8(5H)-one P2X7 receptor antagonists.

Ameriks MK, Ao H, Carruthers NI, Lord B, Ravula S, Rech JC, Savall BM, Wall JL, Wang Q, Bhattacharya A, Letavic MA.

Bioorg Med Chem Lett. 2016 Jan 15;26(2):257-261. doi: 10.1016/j.bmcl.2015.12.052. Epub 2015 Dec 17.

PMID:
26707399
20.

P2X7 receptor antagonism in the treatment of cancers.

Roger S, Pelegrin P.

Expert Opin Investig Drugs. 2011 Jul;20(7):875-80. doi: 10.1517/13543784.2011.583918. Epub 2011 May 27.

PMID:
21619470

Supplemental Content

Support Center